CryoLife (CRY) Tops Q2 EPS by 17c

CryoLife (NYSE: CRY) reported Q2 EPS of $0.12, $0.17 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $76.1 million versus the consensus estimate of $70.97 million.

GUIDANCE:

CryoLife sees Q3 2021 revenue of $296-300 million, versus the consensus of $294 million.

For earnings history and earnings-related data on CryoLife (CRY) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c